Miglitol

alpha-Glucosidase Inhibitor — ALIMENTARY TRACT AND METABOLISM

Key facts

Miglitol is an ofp drug in the alpha-Glucosidase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1996. Its mechanism of action is classified as alpha Glucosidase Inhibitors. DrugCentral lists 12 molecular targets, including Si, GAA and AGL. Recorded indications include Diabetes mellitus type 2.

• Approval status: ofp (first approved 1996 by the FDA).
• Drug class: alpha-Glucosidase Inhibitor.
• Mechanism of action: alpha Glucosidase Inhibitors.
• Molecular targets: Si, GAA, AGL and Gaa (12 listed in DrugCentral).
• Indications: Diabetes mellitus type 2.
• ATC code: A10BF02 (Alpha glucosidase inhibitors).
• Molecular formula: C8H17NO5; molecular weight 207.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Diabetes mellitus type 2

Contraindications (10)

• Gastrointestinal obstruction
• Hypoglycemic disorder
• Infectious disease
• Inflammatory bowel disease
• Kidney disease
• Prolonged-Severe Nausea and Vomiting
• Surgical procedure
• Traumatic injury
• Ulceration of intestine
• Ulcerative colitis

Mechanism & targets

• Mechanism of action (MoA): alpha Glucosidase Inhibitors
• Established pharmacologic class: alpha-Glucosidase Inhibitor

Molecular targets (12)

Target	Gene	Action	Activity
Sucrase-isomaltase, intestinal	Si	unknown	IC50 6.96
Lysosomal alpha-glucosidase	GAA	inhibitor	IC50 6.46
Glycogen debranching enzyme	AGL	unknown	IC50 6.41
Lysosomal alpha-glucosidase	Gaa	unknown	Ki 6.34
Sucrase-isomaltase, intestinal	SI	unknown	IC50 6.30
Maltase-glucoamylase, intestinal	MGAM	inhibitor	Ki 6.00
Lactase-phlorizin hydrolase	LCT	unknown	IC50 4.30
Alpha-glucosidase	aglA	unknown	IC50 4.24
Alpha-mannosidase	—	unknown	IC50 4.12
Glucosylceramidase	GBA	unknown	IC50 4.08
Beta-galactosidase	GLB1	unknown	Ki 4.00
Pancreatic alpha-amylase	AMY2A	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1996-12-18	FDA	—	PHARMACIA AND UPJOHN

ATC classification

ATC code	Therapeutic hierarchy
A10BF02	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Alpha glucosidase inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hypoglycaemia	195.8
Hepatic function abnormal	161.1
Diabetes mellitus inadequate control	106.0
Cerebral infarction	103.4
Renal impairment	77.9
Pemphigoid	69.8
Pneumatosis intestinalis	65.7
Glycosylated haemoglobin increased	59.3
Ketosis	55.8
Liver disorder	52.0
Hyperglycaemia	49.3
Anti-insulin antibody positive	48.1

Chemical structure

• Molecular formula: C₈H₁₇NO₅
• Molecular weight: 207.23 g/mol
• CAS number: 72432-03-2
• InChIKey: IBAQFPQHRJAVAV-ULAWRXDQSA-N
• PubChem CID: 441314

OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Miglitol used for?

DrugCentral lists the following indications for Miglitol: Diabetes mellitus type 2.

How does Miglitol work?

Miglitol is classified as alpha Glucosidase Inhibitors; its molecular targets in DrugCentral include Si, GAA (inhibitor), AGL and Gaa.

When was Miglitol first approved?

Miglitol was first approved by the FDA in 1996.

What drug class does Miglitol belong to?

Miglitol is in the alpha-Glucosidase Inhibitor class.

What is the chemical formula of Miglitol?

Miglitol has the molecular formula C8H17NO5 and a molecular weight of 207.23 g/mol.

Sources

• DrugCentral drug card 1806 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1561 — compound record and bioactivity
• PubChem CID 441314 — chemical identifiers
• DrugBank DB00491 — drug record
• FDA UNII 0V5436JAQW — substance identity
• DailyMed: FDA labels for Miglitol — current prescribing information (label search)
• UniProt P10253 (GAA) — target protein
• UniProt P14410 (SI) — target protein
• UniProt O43451 (MGAM) — target protein
• UniProt P09848 (LCT) — target protein
• UniProt P04062 (GBA) — target protein
• UniProt P04746 (AMY2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.